MedTrace Logo

Pilot Imaging Study of Leukemia

NCT03633955 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-23

No results posted yet for this study

Summary

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Conditions

Interventions

DRUG

FLT

F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Jennifer Holter, MD · Stephenson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-19
Primary Completion
2027-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633955 on ClinicalTrials.gov